2025
Comprehensive cost-of-illness analysis of pressure ulcer treatment: A real-world study at a Czech university hospital
KRUPOVA, Lenka; Andrea POKORNÁ; Miroslav KRUPA a Klára BENEŠOVÁZákladní údaje
Originální název
Comprehensive cost-of-illness analysis of pressure ulcer treatment: A real-world study at a Czech university hospital
Autoři
KRUPOVA, Lenka; Andrea POKORNÁ; Miroslav KRUPA a Klára BENEŠOVÁ
Vydání
International Wound Journal, Hoboken, Wiley-Blackwell, 2025, 1742-4801
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30216 Dermatology and venereal diseases
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.500 v roce 2024
Označené pro přenos do RIV
Ano
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
cost analysis; healthcare costs; patients; pressure ulcers; treatment costs
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 24. 2. 2026 08:51, Mgr. Tereza Miškechová
Anotace
V originále
Pressure ulcers (PUs) impose a significant economic burden on healthcare systems, affecting patient quality of life and leading to substantial treatment costs. This study presents a cost-of-illness analysis of PU treatment in hospitalized patients in the Czech Republic, based on real-world clinical data. The analysis was conducted using a comprehensive methodology at a Czech university hospital, involving 304 hospitalizations. The study included all hospitalized patients with PUs. Data were collected employing a bottom-up, person-based approach, which refers to the collection and analysis of cost data at the individual patient level. This method captures detailed resource utilization for each patient. The methodology accounted for both systemic and local costs, including materials, medications, caregiver time, and procedures. The study involved 304 hospitalizations, with a mean length of stay of 13 days. The total cost of PU treatment, excluding pharmacotherapy, had a median of 678, while including pharmacotherapy, the median cost rose to 929. Younger patients incurred higher treatment costs. Significant cost variations were observed among different departments. We developed and applied a novel cost model to quantify the expenses associated with PUs, which accurately highlighted the financial burden in the hospital care setting. We present a rigorous methodology for PU cost-of-illness analysis, providing a valuable tool for future research and clinical practice. This comprehensive approach supports the development of targeted interventions to reduce the incidence and severity of PUs, ultimately improving patient care and reducing healthcare costs.
Návaznosti
| NU20-09-00094, projekt VaV |
|